🟢 Recursion Pharmaceuticals is trading 5% up today despite biotech sector weakness

Recursion Pharmaceuticals is trading at $3.89, up 5.14%, despite weakness across biotechnology stocks.

• The XBI biotech ETF is down 2.04%, suggesting the move is not being driven by a broad sector rally.
• No new company-specific catalyst was identified on September 24, 2026. Earlier positive Tempus partnership news does not clearly explain the move.